Investments and Fair Value Measurements - Narrative (Details)					1 Months Ended	2 Months Ended	3 Months Ended
	Sep. 20, 2020 USD ($) shares	Jan. 02, 2020 USD ($)	Apr. 25, 2019	Nov. 01, 2018 USD ($) $ / shares	Apr. 30, 2021 USD ($)	Mar. 02, 2020 USD ($)	Apr. 04, 2021 USD ($) fund	Mar. 29, 2020 USD ($)	Dec. 29, 2019 USD ($)	Feb. 28, 2021 USD ($)	Jan. 03, 2021 USD ($)
Schedule of Investments [Line Items]
Marketable equity securities							$ 197,000,000				$ 376,000,000
Marketable equity securities unrealized (losses) and gains							(58,000,000)	$ 3,000,000
Losses on marketable equity securities							14,000,000	0
Strategic equity investments, without readily determinable fair values							$ 314,000,000				314,000,000
Number of venture capital investment funds | fund							2
Equity method investments							$ 139,000,000				104,000,000
(Gain) loss on derivative assets related to terminated acquisition							26,000,000	(95,000,000)
GRAIL Inc
Schedule of Investments [Line Items]
Contingent value right, terms	12 years
Cash payments	$ 3,500,000,000
Merger agreement consideration	8,000,000,000
Business combination, equity Interests Issued and Issuable (in shares)	4,500,000,000
Capital raised	1,000,000,000
Business acquisition, contingent value rights, stock consideration aggregate value	$ 850,000,000
Business acquisition, contingent value rights (in shares) | shares	3,035,714
Business Combination, continuation payments	$ 35,000,000
Business combination, threshold of continuation payments	315,000,000
Termination fee	300,000,000
Investment to be made if merger does not occur	$ 300,000,000
GRAIL Inc | Subsequent Event
Schedule of Investments [Line Items]
Business Combination, continuation payments					$ 35,000,000
GRAIL Inc | Payment Rights Of One Billion, Each Twelve Years
Schedule of Investments [Line Items]
Contingent payment rights, first percentage	2.50%
Business acquisition, contingent value rights, revenue threshold	$ 1,000,000,000
GRAIL Inc | Payment Rights Of Above One Billion, Each Twelve Years
Schedule of Investments [Line Items]
Business acquisition, contingent value rights, revenue threshold	$ 1,000,000,000
Contingent payment rights, second percentage	9.00%
GRAIL Inc | Selling, General and Administrative
Schedule of Investments [Line Items]
Business Combination, continuation payments							105,000,000
Pacific Biosciences of California, Inc (PacBio)
Schedule of Investments [Line Items]
Cash payments				$ 1,200,000,000		$ 34,000,000		132,000,000	$ 18,000,000
Share price (in dollars per share) | $ / shares				$ 8.00
Loss on contract termination		$ 98,000,000
Business combination, contingent consideration arrangements, maximum outcome		52,000,000
Equity or debt financing to be raised		$ 100,000,000
Derivative asset							40,000,000
Pacific Biosciences of California, Inc (PacBio) | Selling, General and Administrative
Schedule of Investments [Line Items]
(Gain) loss on derivative assets related to terminated acquisition							(92,000,000)
Pacific Biosciences of California, Inc (PacBio) | Other Operating Income (Expense)
Schedule of Investments [Line Items]
(Gain) loss on derivative assets related to terminated acquisition								(4,000,000)
S B Northstar L P
Schedule of Investments [Line Items]
Business combination, contingent consideration arrangements, maximum outcome										$ 52,000,000
(Gain) loss on derivative assets related to terminated acquisition							26,000,000
Helix Holdings I, LLC
Schedule of Investments [Line Items]
Contingent value right, terms			7 years
Unrealized gain (loss) from contingent value right							10,000,000	(3,000,000)
Pacific Biosciences of California, Inc (PacBio) | S B Northstar L P | Convertible Senior Notes
Schedule of Investments [Line Items]
Principal amount of notes outstanding										$ 900,000,000
Venture Capital Investment Fund (the Fund)
Schedule of Investments [Line Items]
Commitment in new venture capital investment fund							100,000,000
Remaining capital commitment							32,000,000
Second Venture Capital Investment Fund
Schedule of Investments [Line Items]
Commitment in new venture capital investment fund							160,000,000
Remaining capital commitment							140,000,000
Investee
Schedule of Investments [Line Items]
Revenue from transactions with strategic investees							13,000,000	$ 13,000,000
Variable Interest Entity, Primary Beneficiary | GRAIL, Inc.
Schedule of Investments [Line Items]
Net Assets							$ 250,000,000				$ 250,000,000